1. Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study - Full Text View - ClinicalTrials.gov [Internet]. [cited 2021 Nov 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT04166318
2. COMET Initiative | A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus [Internet]. [cited 2021 Nov 14]. Available from: https://www.comet-initiative.org/Studies/Details/1271
3. Wilkinson JR, Morris EJA, Downing A, Finan PJ, Aravani A, Thomas JD, et al. The rising incidence of anal cancer in England 1990-2010: a population-based study. Color Dis [Internet]. 2014 Jul [cited 2019 Jul 18];16(7):O234–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24410872
4. Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Jemal A. International trends in anal cancer incidence rates. Int J Epidemiol [Internet]. 2016 Oct 27 [cited 2019 Jul 18];46(3):dyw276. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27789668
5. Sekhar H, Malcomson L, Kochhar R, Sperrin M, Alam N, Chakrbarty B, et al. Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014). Br J Cancer [Internet]. 2020 Mar 17 [cited 2021 Nov 14];122(6):749–58. Available from: https://pubmed.ncbi.nlm.nih.gov/31932755/
6. James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol [Internet]. 2013;14(6):516–24. Available from: https://pubmed.ncbi.nlm.nih.gov/23578724/
7. Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol [Internet]. 2012;30(16):1941–8. Available from: https://pubmed.ncbi.nlm.nih.gov/22529257/
8. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, Thomas CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA [Internet]. 2008;299(16):1914–21. Available from: https://pubmed.ncbi.nlm.nih.gov/18430910/
9. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol [Internet]. 1996;14(9):2527–39. Available from: https://pubmed.ncbi.nlm.nih.gov/8823332/
10. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastro. J Clin Oncol [Internet]. 1997;15(5):2040–9. Available from: https://pubmed.ncbi.nlm.nih.gov/9164216/
11. Northover JMA, Arnott SJ, Cunningham D, Gallagher J, Gray R, Hardcastle J, et al. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet [Internet]. 1996;348(9034):1049–54. Available from: http://www.thelancet.com/article/S0140673696034095/fulltext
12. Fish R, Sanders C, Ryan N, Van Der Veer S, Renehan AG, Williamson PR. Systematic review of outcome measures following chemoradiotherapy for the treatment of anal cancer (CORMAC).
13. Fish R, Sanders C, Adams R, Brewer J, Brookes ST, DeNardo J, et al. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol [Internet]. 2018 Dec 1 [cited 2021 Oct 15];3(12):865–73. Available from: http://www.thelancet.com/article/S2468125318302644/fulltext
14. Fish R, Sanders C, Williamson PR, Renehan AG. Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer. BMJ Open [Internet]. 2017 Nov 1 [cited 2021 Oct 15];7(11):e018726. Available from: https://bmjopen.bmj.com/content/7/11/e018726
15. COMET Initiative | Plain language summaries [Internet]. [cited 2021 Nov 8]. Available from: https://comet-initiative.org/Resources/PlainLanguage
16. Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer [Internet]. 2014 [cited 2021 Nov 14];50(17):2983–93. Available from: https://pubmed.ncbi.nlm.nih.gov/25256896/
17. Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, et al. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer [Internet]. 2020 May 1 [cited 2021 Nov 14];130:63–71. Available from: https://pubmed.ncbi.nlm.nih.gov/32172199/
18. Prinsen CAC, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select outcome measurement instruments for outcomes included in a “Core Outcome Set” - a practical guideline. Trials [Internet]. 2016 Sep 13 [cited 2021 Nov 14];17(1). Available from: https://pubmed.ncbi.nlm.nih.gov/27618914/
19. Medicines Agency E. Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of medicinal products for the treatment of asthma. 2015 [cited 2021 Nov 9]; Available from: www.ema.europa.eu/contact
20. Health Technology Assessment (HTA) Programme stage 2 guidance notes (REALMS) [Internet]. [cited 2021 Nov 9]. Available from: https://www.nihr.ac.uk/documents/health-technology-assessment-hta-programme-stage-2-guidance-notes-realms/27817
21. Mason SJ, Catto JWF, Downing A, Bottomley SE, Glaser AW, Wright P. Evaluating patient‐reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus‐based Standards for the selection of health Measurement INstruments (COSMIN) checklist. Bju Int [Internet]. 2018 Nov 1 [cited 2021 Nov 14];122(5):760. Available from: /pmc/articles/PMC6221027/